A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). The unknown etiology of CFS/ME, and complications arising from its heterogeneous nature, contributes to the lack of clear evidence for pharmaceutical interventions. PubMed, 05/23/2016. (Also see Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.)
(Case Report): Posterior reversible encephalopathy syndrome in a patient with mixed connective tissue disease. It is hard to accurately determine whether posterior reversible encephalopathy syndrome in this case is a complication of cyclophosphamide or a condition that resulted from the mixed connective tissue disease flare-up. BioMed Central, Journal of Medical Case Reports 2016. (Also see Mixed Connective Tissue Disease)
MicroRNA–125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis (RA). The expression of miR–125b in peripheral blood mononuclear cells of treatment–naïve patients may present a novel biomarker for monitoring the treatment outcome during the early phase of RA. BioMed Central, Arthritis Res Ther, 2016 Jun 2;18(1):124. (Also see Treatments for Rheumatoid Arthritis)
Non–conventional antiphospholipid (APL) antibodies in patients with clinical obstetrical APS: prevalence and pregnancies treatment efficacy. In this study 68% of patients with clinical criteria for obstetrical antiphospholipid syndrome seronegative for conventional APL have non–conventional APL. Seminars in Arthritis and Rheumatism, 06/03/2016. (Also see Antiphospholipid Syndrome)
Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. The proposed mechanisms for shared pathogenesis between psoriatic diseases and cardiovascular diseases are inflammation, insulin resistance, dyslipidemia, angiogenesis, oxidative stress, and endothelial dysfunction. PubMed, Rheumatol Int, 05/29/2016. (Also see Psoriasis and Psoriatic Arthritis)
Proton pump inhibitors use and change in bone mineral density. The results of this study showed that PPI use in subjects without risk factors of osteoporosis determined by the femoral T–score compared with the control group was associated with increased risk of developing osteoporosis and osteopenia in the femur bones. Wiley Online Library, 05/31/2016. (Also see Osteoporosis)
Serum Growth differentiation factor–15 (GDF–15) level in Behçet's disease: relationships between disease activity and clinical parameters. GDF–15 may play a role in the progression and pathway of Behçet's joint involvement and erythema nodosum that is independent of classic inflammatory response measures. PubMed, Int J Dermatol, 05/21/2016. (Also see Behçet's Disease)
Muscle biopsy in combination with myositis–specific autoantibodies aids prediction of outcomes in juvenile dermatomyositis. Muscle pathology, in combination with MSA, predicts the risk of remaining on treatment in JDM and may be useful for discussing probable treatment length with parents and patients. PubMed, Arthritis Rheumatol, 05/23/2016. (Also see Dermatomyositis)
How compelling are the data for Epstein–Barr virus (EBV) being a trigger for systemic lupus (SLE) and other autoimmune diseases? Collectively, the interplay between an impaired immune system and the cumulative effects of EBV and other viruses results in frequent reactivation of EBV and enhanced cell death. PubMed, Curr Opin Rheumatol, 2016 Jul;28(4):398-404. (Also see Lupus in Overlap and Complications)
Ranges of motion after reverse shoulder arthroplasty improve significantly the first year after surgery in patients with rheumatoid arthritis. After shoulder joint replacement, the range of shoulder motion showed substantial changes during the first year only and should be taken into account when scheduling control visits, planning rehabilitation, and predicting the use of community services after the surgery. PubMed, Eur J Orthop Surg Traumatol, 05/19/2016. (Also see Treatments for Rheumatoid Arthritis)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: